Zibb.com: Biogen Idec Incorporated (Industry News & Blogs)

Receptos, Led By Biogen Idec Vets and Scripps Stars, Snags $25M F...

Mon, 23 Nov 2009 08:00:08 GMT

Receptos, a San Diego-based biotech startup formed by a number of Biogen Idec veterans, has nailed down $25 million in venture capital to develop a vivid new

Biogen shareholder slams CEO pay, calls for measures to boost sto...

Fri, 20 Nov 2009 19:39:12 GMT

’s largest investors is criticizing chief executive James Mullen’s compensation package and other corporate spending initiatives in an effort to goad the company into boosting its stock performance. In a letter sent to Mullen and the Cambridge, Mass.

Genentech (South SF) and Biogen Idec, Inc. (Massachusetts) Receiv...

Thu, 19 Nov 2009 12:00:00 GMT

SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB - News) announced today that the U.S.

Genentech, Biogen Idec cancer drug rejected

Thu, 19 Nov 2009 10:35:00 GMT

The Food and Drug Administration has turned down a request by two biotech companies seeking approval for a drug as a treatment for chronic lymphocytic leukemia.

Genentech and Biogen Idec obtain FDA complete response for leukem...

Thu, 19 Nov 2009 09:53:19 GMT

Genentech, a wholly-owned member of the Roche Group, and Biogen Idec have reported that the FDA issued a complete response on their applications for Rituxan plus fludarabine and cyclophosphamide for the treatment of people with previously untreated and previously treated chronic lymphocytic

Genentech and Biogen Idec Receive a Complete Response from the FD...

Thu, 19 Nov 2009 01:00:00 GMT

South San Francisco, Calif. and Cambridge, Mass. 18 November 2009 Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA

Genentech, Biogen Get FDA Request on Rituxan

Wed, 18 Nov 2009 22:52:17 GMT

Genentech Inc. and partner Biogen Idec Inc. said Wednesday the Food and Drug Administration is withholding a decision to expand approval of Rituxan as a leukemia treatment, pending further discussion.

Genentech, Biogen get FDA request on Rituxan

Wed, 18 Nov 2009 21:48:25 GMT

Genentech Inc. and partner Biogen Idec Inc. said Wednesday the Food and Drug Administration has asked for more information before considering approving Rituxan as a leukemia treatment. The drug is already approved as a treatment for rheumatoid arthritis and...

Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Signi...

Tue, 27 Oct 2009 21:45:00 GMT

DUBLIN & SAN DIEGO--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN - News) and Biogen Idec (NASDAQ: BIIB - News) today

Biogen, Elan lead drug stocks lower

Sun, 25 Oct 2009 19:54:35 GMT

Biotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directory

Biogen Idec shares slip on Tysabri worries

Fri, 23 Oct 2009 18:46:09 GMT

Notes from the European Medicines Agency’s meeting Friday alludes to reports of 23 cases of PML in Tysabri patients since the drug returned to the market.

Biogen, Elan shares plummet on new Tysabri review - Reuters

Fri, 23 Oct 2009 17:22:21 GMT

* European regulators to review risk, benefit of Tysabri * Review follows reports of 23 cases of PML worldwide * Shares of Biogen down 5.5 pct; Elan shares fall 20 pct (Updates share prices) By

STOCKS NEWS US-Biogen, Elan down on new review of Tysabri

Fri, 23 Oct 2009 16:56:00 GMT

Stocks on the move Real Frankfurt: BJU F - news -time Equity news U S stock market report 1234 ET 23Oct2009-Biogen Elan Dublin: DRX IR - news down on new review of Tysabri --------------------------------------------------------------------------- Shares of Biogen Idec NASDAQ: BIIB - news and Elan

Biogen, Elan fall; Dr. Reddy's rallies

Fri, 23 Oct 2009 14:38:00 GMT

Partners Biogen Idec and Elan Corp. lead drug stocks lower in early activity as shares of the companies fall on news that European regulators are reviewing the safety of their multiple sclerosis drug Tysabri.

Biogen Idec downgraded to "underperform"

Wed, 21 Oct 2009 21:17:27 GMT

NEW YORK, October 21 (newratings.com) - Analysts at BMO Capital Markets downgrade Biogen Idec (ticker: BIIB) from "market perform" to "underperform." [more]

All Tysabri, All the Time

Tue, 20 Oct 2009 19:47:24 GMT

(Nasdaq: BIIB) biggest seller, but it was the focus of much of the company's conference call today -- and rightfully so. The multiple sclerosis drug is growing at a 21% year-over-year clip compared with Avonex, its top revenue-generator, which increased just 1% year over year.